Alivio Therapeutics is developing the only inflammation-targeting technology that exists which allows for selective modulation of the immune system at the site of inflammation while avoiding systemic immunosuppression, which is a long sought-after goal in the treatment of auto-immune disease. The platform has been validated in ten different preclinical models of inflammatory disease with publications in top tier journals inclu...
Alivio Therapeutics is developing the only inflammation-targeting technology that exists which allows for selective modulation of the immune system at the site of inflammation while avoiding systemic immunosuppression, which is a long sought-after goal in the treatment of auto-immune disease. The platform has been validated in ten different preclinical models of inflammatory disease with publications in top tier journals including Science Translational Medicine and Nature Communications. The company is developing an internal pipeline of drugs for difficult-to-treat gastrointestinal diseases that leverage the unique nature of the platform.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.